Here are 1-3 brief analogies for Guardant Health:

• Guardant Health is like a "23andMe for cancer detection."
• It's also like a "Ring doorbell for your body, giving early warnings about cancer."
• Furthermore, it's like a "Bloomberg Terminal for oncology research data."

• Advanced Cancer Liquid Biopsy Tests: Provide comprehensive genomic profiling for advanced stage cancer using blood samples.
• Guardant Reveal Test: Used for neoadjuvant and adjuvant treatment selection in early-stage cancer patients.
• LUNAR-2 Test: In development for the early detection of colorectal cancer in asymptomatic individuals.
• GuardantINFORM: An in-silico research platform comprising a clinical-genomic liquid biopsy dataset.
• Biopharmaceutical Development Services: Offers comprehensive services including companion diagnostic development, clinical study support, and regulatory assistance to biopharma and medical institutions.

Major Customers of Guardant Health (GH)

Guardant Health (GH) primarily sells its products and services to other companies and organizations, rather than directly to individual consumers. The company's major customers, as identified from the provided description, fall into the following categories:

• Biopharmaceutical Companies: Guardant Health offers specialized development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, and testing development and support. They also provide access to the GuardantINFORM research platform and GuardantConnect solution, which links patients with relevant clinical trials, primarily benefiting biopharmaceutical companies engaged in drug discovery and development.
• Medical Institutions: This category includes hospitals, clinics, and academic medical centers. These institutions are customers for Guardant Health's liquid biopsy-based tests (e.g., Guardant360, GuardantOMNI, Guardant Reveal) for advanced and early-stage cancer detection and treatment selection. They also engage Guardant Health for various development services related to clinical studies and diagnostic support.

The provided company description does not list specific names of individual customer companies within these categories.

• Illumina, Inc. (ILMN)
• Danaher Corporation (DHR)
• Twist Bioscience Corporation (TWST)
• Thermo Fisher Scientific, Inc. (TMO)

Helmy Eltoukhy Co-CEO and Chairman

Helmy Eltoukhy is the Chairman and co-CEO of Guardant Health, which he co-founded in 2012 with Dr. AmirAli Talasaz. Prior to Guardant Health, Eltoukhy co-founded Avantome in 2007 to commercialize semiconductor sequencing, which was acquired by Illumina in 2008. While at Illumina, he served as senior director of Advanced Technology Research. Eltoukhy received his PhD, MS, and BS degrees in electrical engineering from Stanford University.

AmirAli Talasaz Co-CEO

AmirAli Talasaz is the co-CEO of Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Before co-founding Guardant Health, Talasaz was senior director of Diagnostics Research at Illumina, where he led efforts for emerging clinical applications of next-generation genomic analysis. He also founded Auriphex Biosciences, a company focused on purifying and genetically analyzing circulating tumor cells for cancer management, whose technology was acquired by Illumina in 2009. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.

Michael Bell Chief Financial Officer

Michael Bell is the Chief Financial Officer at Guardant Health, a position he has held since January 2021. He has over 30 years of experience and has previously served as CFO of other clinical diagnostic companies, including CareDx, Metabiota, Singulex, and Novartis Diagnostics. Bell also worked in public accounting and consulting at Deloitte and Ernst & Young. He holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester and is a Fellow of the Institute of Chartered Accountants in England and Wales.

Darya Chudova Chief Technology Officer

Darya Chudova is the Chief Technology Officer at Guardant Health, where she oversees the company's technology strategy and development. She previously served as Senior Vice President, leading the technical development of Guardant's Shield™ screening product and the Guardant360 LDT and CDx therapy selection portfolio. Before joining Guardant Health, Chudova developed tools for clinical diagnostics and genomic expression data interpretation at Veracyte, Inc., and non-invasive prenatal testing at Illumina, Inc.

Kumud Kalia Chief Information Officer

Kumud Kalia is the Chief Information Officer at Guardant Health, responsible for the company's enterprise applications, information technology, data engineering, and security teams. Prior to Guardant Health, Kalia held CIO and CTO roles at Cylance, Akamai, and Direct Energy, and leadership positions at UBS and Morgan Stanley. He holds degrees in Electronic Engineering from Bangor University and Cybersecurity from UC Berkeley, and is a Fellow of both the Institution of Engineering and Technology and the British Computer Society.

The key risks to Guardant Health (GH) include:

1. Ongoing Unprofitability and Significant Cash Burn: Guardant Health continues to incur substantial net losses and negative cash flow, necessitating continuous investment in research, development, and commercialization efforts. This financial weakness could limit the company's ability to expand capacity and commercialize new products, potentially requiring additional external financing through debt or equity dilution in the future. As of December 31, 2025, the company had an accumulated deficit of $3.0 billion.
2. Reimbursement and Regulatory Challenges: The company's financial performance is heavily reliant on favorable reimbursement policies from third-party payers, including Medicare and private insurers, for its liquid biopsy tests such as SHIELD and Guardant Reveal. Changes in coverage, reimbursement rates, or evolving regulatory oversight from the FDA for lab-developed tests (LDTs) and screening guidelines could significantly impede the adoption and commercial success of Guardant Health's products. For instance, the clinical trial data for the SHIELD test, particularly its sensitivity compared to competitors, has raised questions about its commercial prospects and ability to secure optimal reimbursement terms.
3. Intense Competition and Market Share Pressure: Guardant Health operates in a highly competitive landscape within the precision oncology and liquid biopsy markets. Established diagnostics companies and emerging rivals, including Exact Sciences, Natera, Foundation Medicine (owned by Roche), Thermo Fisher Scientific, Illumina (GRAIL), and Freenome, pose a significant threat. Competitors may develop more effective or cost-efficient diagnostic alternatives, potentially leading to reduced market share, pricing pressures, and a slower uptake of Guardant Health's offerings.

The following are clear emerging threats for Guardant Health:

• Multi-Cancer Early Detection (MCED) Tests from Competitors: The commercialization and increasing adoption of multi-cancer early detection tests, such as GRAIL's Galleri (developed by Illumina), pose a significant threat. While Guardant Health is developing its LUNAR-2 test for early colorectal cancer detection, Galleri targets the broader and potentially massive multi-cancer screening market. If competitors establish a dominant market position and widespread clinical integration in MCED, it could significantly limit Guardant Health's future growth and market share in this highly disruptive and rapidly emerging diagnostic category.
• Advanced Minimal Residual Disease (MRD) Tests from Competitors: The strong market penetration and clinical adoption of highly sensitive and validated minimal residual disease (MRD) tests from competitors, such as Natera's Signatera, represent a clear emerging threat. Guardant Health offers its Guardant Reveal test for MRD monitoring. However, Signatera's tumor-informed personalized approach, robust clinical evidence across multiple cancer types, and established reimbursement pathways have positioned it as a leading contender in this crucial and rapidly expanding segment of cancer diagnostics, potentially challenging Guardant Health's ability to gain significant market share.

Guardant Health (symbol: GH) operates in several significant addressable markets for its main products and services:

• Guardant360 (Therapy Selection for Advanced Cancer): The therapy selection market, where Guardant360 is a primary offering, is estimated to be around $10 billion, primarily focused on the U.S. market.
• Guardant Reveal (Minimal Residual Disease - MRD): The addressable market for Minimal Residual Disease (MRD) detection, which Guardant Reveal targets, is approximately $20 billion. Guardant Reveal also targets a global solid tumor cancer treatment market size of $5.64 billion in 2025.
• Guardant Shield (Colorectal Cancer Screening): The total U.S. addressable market for average-risk individuals eligible for colorectal cancer screening is estimated at a potential value of $50 billion.
• Shield Multi-Cancer Detection (MCD): This pipeline product, aimed at early detection of multiple cancers, has a projected global total addressable market of approximately $2.86 billion by 2030.

Here are 3-5 expected drivers of future revenue growth for Guardant Health (GH) over the next 2-3 years:

1. Accelerated Adoption and Expansion of Shield™ for Colorectal Cancer Screening: Guardant Health's blood-based colorectal cancer screening test, Shield, is consistently highlighted as a significant multi-year revenue growth driver. The company saw substantial revenue and volume growth from Shield in Q4 2025, with 2026 guidance projecting a meaningful increase in screening revenue and tests. Key factors include achieving ADLT (Advanced Diagnostic Laboratory Test) status with a favorable reimbursement rate of $1,495, gaining a first-mover advantage, and strong provider adoption. Strategic partnerships, such as with Quest Diagnostics, and direct-to-consumer marketing efforts are further expanding its market reach.
2. Continued Growth of the Core Oncology Business: The company's established oncology portfolio, including Guardant360 (Liquid and Tissue), Guardant Reveal, and GuardantOMNI, remains a strong revenue engine. Management expects oncology revenue to grow by 25% to 27% in 2026, with anticipated volume growth of approximately 30%. This growth is driven by expanding clinical utility through new "Smart Liquid Biopsy" applications for Guardant360, leading to increased adoption and test volumes.
3. Expansion of Biopharma and Data Partnerships: The biopharma and data segment is expected to contribute consistently to revenue growth, with projections in the low double-digit range for 2026. This growth is fueled by ongoing collaborations with pharmaceutical companies, new program starts, and Guardant Health's leadership in companion diagnostics (CDx), boasting 25 approvals to date across various regions and a robust pipeline of new CDx programs.
4. Strategic Market Expansion and Increased Access: Guardant Health is actively pursuing initiatives to broaden access to its tests. Partnerships, such as the collaboration with Quest Diagnostics for Shield, aim to integrate the test into numerous physicians' electronic medical record (EMR) systems, thereby significantly enhancing market penetration. Additionally, the company is undertaking international expansion for Shield, supported by acquisitions like MetaSight.
5. Potential for New Product Indications and Enhanced Reimbursement: Beyond the ongoing Shield rollout, Guardant Health is working on securing additional reimbursement coverage for Guardant Reveal in various cancer types through MolDX. There is also an anticipation of FDA approval for Guardant360 in new indications in the latter half of 2026, which could further boost its market potential and revenue.

[1] Share Repurchases

• Guardant Health intended to repurchase approximately $45 million of its common stock in connection with privately negotiated exchange agreements in February 2025.

[2] Share Issuance

• In November 2025, Guardant Health priced an upsized underwritten public offering of 3,333,333 shares of its common stock at $90.00 per share, with an option for underwriters to purchase additional shares.
• Concurrently in November 2025, the company also priced an offering of $350.0 million aggregate principal amount of convertible senior notes due 2033, an amount that was upsized from a previously announced $300.0 million. In total, $402.5 million principal amount of 0% convertible senior notes due 2033 were issued in November 2025.
• In February 2026, Guardant Health filed a shelf registration for $510.17 million for 4,795,700 common shares tied to employee stock plans.

[4] Outbound Investments

• In December 2025, Guardant Health acquired MetaSight Diagnostics Ltd. for $149 million, comprising $59 million in upfront cash and up to $90 million in potential milestone payments.
• In June 2022, Guardant Health acquired Guardant Health AMEA for $178 million.